Overview

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Status:
Completed

Trial end date:
2000-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of single rising oral doses of BIA 2-093 (proposed doses 20mg, 50mg, 100mg, 200mg, 400mg, 600mg, 900mg and 1200mg) in groups of 8 healthy male adult volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Bial - Portela C S.A.

Treatments:

Eslicarbazepine acetate